Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.

  title={Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.},
  author={Angel L Pey and Ming Ying and N. Cremades and A. Vel{\'a}zquez-Campoy and T. Scherer and B. Th{\"o}ny and J. Sancho and A. Mart{\'i}nez},
  journal={The Journal of clinical investigation},
  volume={118 8},
  • Angel L Pey, Ming Ying, +5 authors A. Martínez
  • Published 2008
  • Biology, Medicine
  • The Journal of clinical investigation
  • Phenylketonuria (PKU) is an inborn error of metabolism caused by mutations in phenylalanine hydroxylase (PAH). Over 500 disease-causing mutations have been identified in humans, most of which result in PAH protein misfolding and increased turnover in vivo. The use of pharmacological chaperones to stabilize or promote correct folding of mutant proteins represents a promising new direction in the treatment of misfolding diseases. We performed a high-throughput ligand screen of over 1,000… CONTINUE READING
    135 Citations
    Novel pharmacological chaperones that correct phenylketonuria in mice.
    • 59
    • PDF
    New perspectives for pharmacological chaperoning treatment in methylmalonic aciduria cblB type.
    • 4
    Phenylalanine Hydroxylase Misfolding and Pharmacological Chaperones†
    • 49
    • Highly Influenced
    • PDF
    Discovery of compounds that protect tyrosine hydroxylase activity through different mechanisms.
    • 7
    New protein structures provide an updated understanding of phenylketonuria.
    • E. Jaffe
    • Chemistry, Medicine
    • Molecular genetics and metabolism
    • 2017
    • 15
    Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo.
    • 41
    • PDF
    Potential Pharmacological Chaperones for Cystathionine Beta-Synthase-Deficient Homocystinuria.
    • 15
    • PDF
    The G46S-hPAH mutant protein: a model to study the rescue of aggregation-prone PKU mutations by chaperones.
    • 8
    • Highly Influenced
    Structure of full-length human phenylalanine hydroxylase in complex with tetrahydrobiopterin
    • 1
    • PDF


    Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria.
    • 49
    Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations
    • 117
    • PDF
    Characterization of the mouse phenylalanine hydroxylase mutation Pah(enu3).
    • 9
    Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs.
    • 122
    Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria.
    • 172
    Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations.
    • 153
    • PDF
    Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.
    • 59
    The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
    • 173
    • PDF